[ad_1]
FibroGen Inc. FGEN,
Shares fell in the extended session on Tuesday after the biotech drugmaker said an analysis of data from its anemia drug revealed inconsistencies in the classification of some safety data. FibroGen shares fell 22% after hours, after falling 2.8% to close at $ 34.62 in the regular session. The company said it wanted to clarify that the safety analyzes of its drug roxadustat, intended to treat anemia that results from chronic kidney disease, included stratifications that had been changed. “As members of management prepared for the next FDA Advisory Board meeting, we realized that key cardiovascular safety analyzes included post-hoc changes in stratification factors,” said Enrique Conterno, Director General of FibroGen, in a statement. The company said it was conducting an “internal review to ensure that such issues do not recur in the future.”
Source link
